Fresenius Medical Care AG's SEC filings document its reporting as a German foreign private issuer with ordinary shares and ADRs listed in Frankfurt and New York. Form 6-K reports furnish quarterly and full-year results, press releases, IFRS financial figures, non-GAAP reconciliations, share buyback disclosures, and material updates affecting the company's kidney care operations.
The filing record also covers the Form 20-F annual report, audited consolidated financial statements, Annual General Meeting materials, ADR voting instruction cards, compensation reporting, Supervisory Board reports, and Management Board explanatory reports under German corporate law. Segment disclosures identify Care Delivery, Care Enablement, Value-Based Care, health care services, and health care products.
Fresenius Medical Care AG furnished a Form 6-K announcing its third quarter results for the period ended September 30, 2025. The submission includes a press release (Exhibit 99.1) and accompanying financial figures (Exhibit 99.2).
The company highlights non-GAAP measures alongside IFRS results, including EBITDA, free cash flow, net leverage ratio (net debt to adjusted EBITDA), constant-currency metrics, and results adjusted for special items, with reconciliations provided in the exhibits. The exhibits are furnished, not filed.